타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 자동 수집 갱신 권장 · 9월 2일
현재 선택: 2개 · 임상 갱신 필요 2개 · Data Tier에서 열림
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Gemcitabine Hydrochloride (Gemcitabine Hydrochloride) K-Group, Beta, Inc., a wholly owne…·FRα 165 trials | |
|---|---|---|
Overview Program | Gemcitabine Hydrochloride | Hydroxyurea (HU) |
Overview Company | K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc | Bionoxx Inc. |
Overview Modality | ADC | ANTIBODY |
Overview Target | FRα | FRα |
Overview Indication | Fallopian Tube Carcinosarcoma; Fallopian Tube Clear Cell Adenocarcinoma | Treatment-Refractory Solid Tumors |
Overview Phase | PHASE_2 | PHASE_1 |
Overview Status | ACTIVE | RECRUITING |
Overview Content status | Limited Data | Limited Data |
Overview Data Confidence | Editorial scope · limited data | Editorial scope · limited data |
Overview Development Signal | Development Signal · Emerging | Development Signal · Watch |
Overview Approval status | Investigational | Investigational |
Technology Linker | linker-payload technologies | — |
MoA Mechanism | of ProAgio, which includes reducing hypoxia and modulating TME | , represents a significant advance in phytomedicine-based approaches to obesity treatment |
MoA Biomarker | HER2 expression | biomarker in Parkinson's disease (PD), but its levels are influenced by dopamine replacement therapy (DRT), c |
Clinical Program phase | PHASE_2 | PHASE_1 |
Clinical Trial activity | No active/completed counts | No active/completed counts |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 자동 수집 갱신 권장 · 9월 2일
현재 선택: 2개 · 임상 갱신 필요 2개 · Data Tier에서 열림
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Gemcitabine Hydrochloride (Gemcitabine Hydrochloride) K-Group, Beta, Inc., a wholly owne…·FRα 165 trials | |
|---|---|---|
Overview Program | Gemcitabine Hydrochloride | Hydroxyurea (HU) |
Overview Company | K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc | Bionoxx Inc. |
Overview Modality | ADC | ANTIBODY |
Overview Target | FRα | FRα |
Overview Indication | Fallopian Tube Carcinosarcoma; Fallopian Tube Clear Cell Adenocarcinoma | Treatment-Refractory Solid Tumors |
Overview Phase | PHASE_2 | PHASE_1 |
Overview Status | ACTIVE | RECRUITING |
Overview Content status | Limited Data | Limited Data |
Overview Data Confidence | Editorial scope · limited data | Editorial scope · limited data |
Overview Development Signal | Development Signal · Emerging | Development Signal · Watch |
Overview Approval status | Investigational | Investigational |
Technology Linker | linker-payload technologies | — |
MoA Mechanism | of ProAgio, which includes reducing hypoxia and modulating TME | , represents a significant advance in phytomedicine-based approaches to obesity treatment |
MoA Biomarker | HER2 expression | biomarker in Parkinson's disease (PD), but its levels are influenced by dopamine replacement therapy (DRT), c |
Clinical Program phase | PHASE_2 | PHASE_1 |
Clinical Trial activity | No active/completed counts | No active/completed counts |
추천 비교
추천 비교